| Title |
Recent Advances in RNA Interference Therapeutics for CNS Diseases
|
|---|---|
| Published in |
Neurotherapeutics, July 2013
|
| DOI | 10.1007/s13311-013-0183-8 |
| Pubmed ID | |
| Authors |
Pavitra S. Ramachandran, Megan S. Keiser, Beverly L. Davidson |
| Abstract |
Over the last decade, RNA interference technology has shown therapeutic promise in rodent models of dominantly inherited brain diseases, including those caused by polyglutamine repeat expansions in the coding region of the affected gene. For some of these diseases, proof-of concept studies in model organisms have transitioned to safety testing in larger animal models, such as the nonhuman primate. Here, we review recent progress on RNA interference-based therapies in various model systems. We also highlight outstanding questions or concerns that have emerged as a result of an improved (and ever advancing) understanding of the technologies employed. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 44 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 11 | 25% |
| Researcher | 9 | 20% |
| Student > Ph. D. Student | 8 | 18% |
| Student > Master | 6 | 14% |
| Student > Doctoral Student | 3 | 7% |
| Other | 4 | 9% |
| Unknown | 3 | 7% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 13 | 30% |
| Biochemistry, Genetics and Molecular Biology | 10 | 23% |
| Medicine and Dentistry | 5 | 11% |
| Neuroscience | 4 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Other | 4 | 9% |
| Unknown | 6 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 May 2023.
All research outputs
#4,759,600
of 25,371,288 outputs
Outputs from Neurotherapeutics
#483
of 1,308 outputs
Outputs of similar age
#38,319
of 206,705 outputs
Outputs of similar age from Neurotherapeutics
#4
of 10 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,308 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.2. This one has gotten more attention than average, scoring higher than 62% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,705 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.